Biogen's Q3 revenue declines 10% as focus shifts to new Alzheimer's and ALS drug candidates
While Biogen’s Q3 revenue dipped by 10% versus the prior year, the company focused its earnings call on two bright prospects — recently unveiled positive results …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
